Clinical Trial

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Name: Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. — clinical trial record (NCT07448116)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of the anti-EGFR/c-Met bispecific antibody MCLA-129 in combination with Ensartinib hydrochloride in patients with advanced solid tumors.

Trial Details

NCT Number	NCT07448116
Lead Sponsor	Betta Pharmaceuticals Co., Ltd.
Conditions	Solid Advanced Tumor
Enrollment	164 participants
Start Date	2026-01-31
Primary Completion	2029-02-01 (estimated)
Study Completion	2029-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-04